The Role of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Oocyte Maturation and Subsequent Pregnancy in Mice

Min Li1,3,*, Yang Yu1,3,*, Jie Yan1,3, Li-Ying Yan1,2, Yue Zhao1,2, Rong Li1,3,4, Ping Liu1,3, Aaron J. Hsueh2,*, Jie Qiao1,3,4,*  
1 Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China, 2 Program of Reproductive and Stem Cell Biology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, United States of America, 3 Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China, 4 Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, The People’s Republic of China

Abstract

It is important to identify effective contraceptive drugs that cause minimal disruption to physiological processes. Phosphodiesterase 3 (PDE3) inhibitors suppress meiosis in oocytes by decreasing the level of cAMP and blocking the extrusion of the first polar body. In this study, we tested the PDE3 inhibitor, cilostazol, as a potential contraceptive agent. The effects of cilostazol treatment in vitro and in vivo on the suppression of oocyte maturation in a mouse model were investigated. The results indicated that treatment with increasing concentrations of cilostazol led to a dose-dependent arrest in meiosis progression. The effective in vitro concentration was 1 μM and was 300 mg/kg in vivo. The effect of cilostazol was reversible. After removal of the drug, meiosis resumed and mouse oocytes matured in vitro, and showed normal chromosome alignment and spindle organization. After fertilization using an ICSI method, the oocytes showed normal morphology, fertilization rate, embryo cleavage, blastocyst formation, and number of viable pups when compared with controls. The offspring showed similar body weight and fertility. In vivo, the mice became infertile if the drug was injected sequentially, and became pregnant following discontinuation of cilostazol. More importantly, no side effects of cilostazol were observed in treated female mice as demonstrated by blood pressure and heart rate monitoring. It is concluded that cilostazol, a drug routinely used for intermittent claudication, can effectively inhibit oocyte maturation in vitro and in vivo, does not affect the developmental potential of oocytes following drug removal and has few side effects in female mice treated with this drug. These findings suggest that cilostazol may be a potential new contraceptive agent that may facilitate an efficacy and safety study of this drug.

Introduction

The current steroid-based contraceptive pills are reversible and effective. They also decrease the incidence of ovarian and endometrial tumors [1]. However, thrombogenic and other side effects in some women taking these steroid-based contraceptive pills have been reported [2], and the effects of these drugs on future generations are still unclear. The ideal contraceptive should act on the ovary to block oocyte maturation during the process of ovulation without disrupting the menstrual cycle.

In mammals, oocyte meiosis is arrested at the germinal vesicle (GV) phase in growing follicles. Before ovulation, the LH surge induces granulosa cells to secrete cyclic adenosine monophosphate (cAMP) which leads to follicle rupture [3,4]. However, in oocytes, a decrease in intra-oocyte cAMP levels is required for the resumption of meiosis. Earlier studies demonstrated that spontaneous maturation of mouse oocytes in vitro when released from their follicles can be reversibly blocked by the addition of a derivative of cAMP or a phosphodiesterase (PDE) inhibitor and the PDE3 was localized in oocytes [5]. Treatment with a PDE3 inhibitor did not affect follicle rupture and reproductive cyclicity in mice but elevated cAMP levels in oocytes and suppressed GV breakdown, leading to a new contraceptive approach [6]. Thus, by increasing the level of cAMP with pharmacological or molecular approaches, one can inhibit meiosis in oocytes and induce contraception.

To date, ORG99935 is one of the widest studied PDE3 inhibitors as a potential contraceptive. Oocytes retrieved from immature follicles were arrested in prophase I with a high efficiency for up to 72 h when cultured with ORG99935 (10 mM) [7]. A series of experiments on macaques found that ORG99935 selectively blocked the spontaneous resumption of meiosis in macaque oocytes in vitro and inhibited oocyte maturation in gonadotropin-stimulated and in natural ovarian cycles in rhesus macaques without affecting follicle rupture [8–10]. The effective dosage of
ORG9935 for oocyte meiotic arrest in rhesus macaques was also determined [11]. It has been proposed that this PDE3 inhibitor could be a potential oral contraceptive. However, treatment with ORG9935 in rodents increased heart rate [6] and ORG9935 is not a clinical medicine approved by the US Food and Drug Administration (FDA). Therefore, it is still necessary to develop other PDE3 inhibitors approved by FDA and study their potential as contraceptives.

Figure 1. Developmental stages of mouse oocytes after treatment of COCs and DOs with cilostazol and ORG9935 at different concentrations for 24 h. As the concentration increased, the percentage of oocytes showing meiotic arrest increased (P<0.05). (A) Cilostazol and (B) ORG9935. Orange dot line represents COCs at GV stage, orange hyphen line represents COCs at GVBD stage, and orange straight line represents COCs at MII stage. Blue DOs dot line represents COCs at GV stage, blue hyphen line represents DOs at GVBD stage, and blue straight line represents DOs at MII stage.

doi:10.1371/journal.pone.0030649.g001

Cilostazol Inhibits Oocyte Maturation
Cilostazol, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)-quinolinone, another PDE3 inhibitor, has been shown to increase cellular levels of cAMP by inhibiting its degradation, it also inhibits platelet aggregation [12], serving as an arterial vasodilator. Importantly, it has been approved as a therapeutic agent for intermittent claudication [13]. However, the possible regulation of oocyte maturation in vitro and in vivo by cilostazol has yet to be studied.

The aim of this study is to investigate the effects of cilostazol on meiotic arrest and maturation of mouse oocytes in vitro as well as the potential use of cilostazol as a contraceptive in vivo in mice. The effects of prior exposure to cilostazol on chromosome alignment and spindle organization in oocytes, development during pregnancy and full-term development of embryos after removal of cilostazol were also studied. Furthermore, the physiology indexes of mice treated with this drug and their offspring was investigated.

**Results**

**Effects of different concentrations of cilostazol on the maturation of mouse oocytes in vitro**

To study the optimal concentration of cilostazol for the inhibition of mouse oocyte maturation, different concentrations of cilostazol were added to the IVM medium containing mouse cumulus-oocyte complexes (COCs) and denuded oocytes (Dos). A dose-dependent suppression of meiotic progression was observed (Fig. 1A). With increased concentrations of cilostazol, the meiotic arrest rate of GV oocytes was also increased, and meiotic arrest was completely inhibited at 1 μmol/L. The effects of different concentrations of ORG9935 on mouse oocytes were also evaluated as a positive control and were consistent with those found in cilostazol treatment (Fig. 1B).

**Reversible effects of cilostazol on the developmental competence of oocytes and embryonic development**

Following removal of cilostazol, meiosis resumed within 20 hours which is normal in IVM. Some of the IVM oocytes which recovered from meiotic arrest were tested for spindle organization and chromosome alignment. The results showed that there was no significant difference between IVM oocytes treated with cilostazol and control IVM oocytes (P>0.05). More than 80% of IVM oocytes in the treatment and control groups showed normal spindle organization and chromosome alignment, and spindle configuration was regarded as morphologically normal when the meiotic spindle showed an oblong structure. Chromosome configuration was regarded as normal when chromosomes were located exclusively on the equatorial plate (Table 1). The representative morphology is shown in Fig. 2.

Some of the IVM oocytes were fertilized using the ICSI method to assess the developmental potential of the oocytes treated with cilostazol. Successful fertilization was assessed by the formation of male and female pronuclear. Some fertilized embryos were cultured in vitro to assess the preimplantation development potential. The rates of fertilization and cleavage in vitro were 78.3% and 83.1%, respectively, which were not significantly different from the control group (P>0.05). The rate of blastocyst formation was also comparable between the two groups, showing no significant difference (P>0.05) (Table 2). Other fertilized embryos were transferred into female recipients to assess full-term development.

![Figure 2. The distribution and organization of microtubules and spindles in IVM oocytes treated and not treated with cilostazol.](https://example.com/figure2.png)

**Table 1. A summary of α-tubulin expression and nuclear location in IVM oocytes in cilostazol treatment and non-treatment groups.**

| Group      | No. of oocytes | Normal Metaphase | Abnormal Metaphase |
|------------|----------------|------------------|-------------------|
| Treatment  | 22             | 16 (72.7)        | 6 (27.3)          |
| Non-treatment | 28             | 21 (75.0)        | 7 (25.0)          |

*Values with same superscripts in the same column are comparable (P>0.05).* 

doi:10.1371/journal.pone.0030649.t001
development potential. The results suggested that there was no significant difference between the treatment and control groups ($P > 0.05$) (Table 2).

Two key physiological indices of offspring were analyzed: body weight and fertility. The results of body weight analysis indicated that there was no significant difference between female and male offspring in the treatment and control groups ($P > 0.05$). However, the body weight of male offspring in the seven-week and sixteen-week age in the treatment group was significantly lower compared with the control group ($P < 0.05$) (Fig. 3A and B). The fertility assessment demonstrated that there were no significant differences between the treatment and control groups ($P > 0.05$), irrespective of whether the female or male mice were mated. No significant differences in litter size and sex ratio were observed between the two groups ($P > 0.05$) (Fig. 3C and D).

**Effects of different concentrations of cilostazol on the oocyte maturation, pregnancy and heart cardiovascular parameters in female mice**

Based on *in vitro* studies, we injected cilostazol into female mice to evaluate its role in the suppression and inhibition of oocyte maturation and pregnancy. Mice treated with ORG9935 acted as positive controls. The results showed that cilostazol had a dose-dependent effect on *in vitro* maturation of oocytes. With increased concentrations of cilostazol, the rate of mature MII oocytes was decreased, and meiotic arrest was completely inhibited at 300 mg/kg, and approximately 14.5% of oocytes treated with ORG9935 were not inhibited and achieved maturation, the effective concentration of ORG9935 was 500 mg/kg (Fig. 4).

Female mice treated with the cilostazol were mated with male mice. The results suggested that the mice injected consecutively with cilostazol did not become pregnant although vaginal plugs were found in the morning. However, mice injected with the same volume of 0.9% physiological saline solution became pregnant and produced offspring after plugs were observed. Following the removal the cilostazol, fertility was restored in female mice within a short time, they became pregnant and produced offspring, and the litter size in treated mice was not significantly different from that in non-treated mice (Fig. 5A and B).

To identify possible side effects of cilostazol in female mice, the blood pressure and heart rate of female mice injected with cilostazol were monitored. The results showed that heart rate was not significantly different between the treatment and control groups ($P > 0.05$), and the results for systolic and diastolic blood pressure (SBP and DBP) were similar (Table 3).

**Discussion**

In the present study, we first described the role of cilostazol, a PDE3 inhibitor, on the suppression of mouse oocyte maturation *in vitro* and *in vivo*, and demonstrated the effects of cilostazol on IVM oocytes and the resulting embryos and offspring. PDEs are enzymes that can degrade and inactivate cAMP [14]. PDE3 is a member of the PDE family, and is found in the oocytes of mice [15], cattle [16], and humans [7]. Inhibition of PDE3 can increase the level of cAMP, resulting in oocyte GVBD blockage [16–25]. PDE3A regulates the resumption of meiosis up to 3 h prior to GVBD and transiently affects meiotic progression [16,26]. PDE3A-deficient mice with oocytes containing increased cAMP levels failed to undergo spontaneous maturation; however, the animals were viable and showed no other abnormalities [26]. Adult cycling rats treated with a PDE3 inhibitor completely prevented viable pregnancy, but maintained estrous cycles (and ovarian hormone production) [6].

Our study showed that cilostazol effectively inhibited mouse oocyte maturation *in vitro* and *in vivo*. These results may provide a potential new approach for future contraceptives. The effective concentration of cilostazol was identified by *in vitro* and *in vivo* experiments using a mouse model, and reversibility tests indicated that the developmental competence of the oocytes was not impaired following removal of the drugs and allowed ovulation and oocyte maturation. In the *in vitro* experiments, ORG9935 suppressed meiosis at the concentration of 1 μmol/L, consistent with the findings of a previous study [16].

It is a concern for users as to whether the developmental competence of oocytes would be impaired by this drug. Using the mouse model, the dynamics of the spindle and chromosome apparatus were identified, and the results suggested that there was no significant difference between the treatment and control groups. Moreover, the resulting fertilized embryos had similar development potential in the preimplantation and full-term development stages as those in the control group. In our study, treatment with cilostazol did not affect the development potential of treated oocytes after drug removal. Similarly, mouse follicles treated with ORG9935 in IVM medium did not affect somatic cell function, differentiation, oocyte growth and maturation [27].

In the present study, we found that cilostazol was safer than ORG9935. Wiersma et al. indicated that ORG9935 could induce an increase in heart rate in rodents. However, in our study, the heart rate in female mice treated with cilostazol was normal and not significantly different to that in the control group. The mating experiment was used to assess the fertility of mice treated with this drug and to determine the safety of this drug. The mice treated with cilostazol were infertile, and immediately became pregnant after its removal. The litter size and sex ratio of the offspring from the treated oocytes and normal IVM oocytes were similar. All these data demonstrate that cilostazol is effective and safer than the PDE3 previously reported.

Furthermore, cilostazol has been approved in the U.S. for the treatment of symptoms of intermittent claudication (IC) since 1999 and for related indications since 1988 in Japan and other Asian countries [28]. Other PDE3 inhibitors such as milrinone have

| Table 2. Effects of cilostazol treatment *in vitro* and *in vivo* on the early and full-term development of ICSI embryos. |
| --- |
| **Group** | No. of oocytes | No. fertilized (%) | Development stage (%) | No. of transferred embryos | No. of full-term fetuses (%) |
| | | | | 2-cell | 8-cell | Blastocyst | | |
| Treatment *in vitro* | 83 | 65 (78.3)$^a$ | 54 (64.1)$^a$ | 33 (42.6)$^a$ | 23 (42.6)$^a$ | 30 | 14 (46.7)$^a$ |
| Control *in vitro* | 77 | 62 (80.5)$^a$ | 50 (80.6)$^a$ | 30 (60.0)$^a$ | 18 (36.0)$^a$ | 30 | 16 (53.3)$^a$ |
| **Note:** Values with same superscripts in the same column are comparable ($P > 0.05$). |
been described as having side effects such as fatal arrhythmias, however, no such side effects have been described for cilostazol [29]. Cilostazol has also been confirmed to be beneficial in different circulatory symptoms [12,30,31]. If the correct dosage is identified to minimize side effects, this agent may be a safe contraceptive.

In conclusion, we found that cilostazol blocked maturation of mouse oocytes both in vitro and in vivo. The reversibility of this drug was determined based on the resumption of oocyte meiosis and blastocyst formation as well as full-term development of fertilized embryos. The effectiveness of cilostazol was proved by the mating experiment, which indicated the potential of cilostazol as a contraceptive drug. These findings may not only provide a new choice of contraceptive, but may promote and facilitate future studies on the mechanisms of action of contraceptive drugs on oocyte and embryo development.

Materials and Methods

All chemicals were from Sigma Chemical Co. (Sigma, USA) unless otherwise indicated. ORG9935 and cilostazol were stored at 10 mM in dimethyl sulfoxide (DMSO) at −20°C. In preliminary experiments, the highest concentration of the DMSO carrier (0.1% v/v) was tested for 24 h in IVM medium and no effect on maturation was observed.

Experimental design

A schematic diagram of the study is shown in Figure S1. Experiment 1 was primarily designed to determine the lowest effective dose of cilostazol that arrested oocytes in vitro at the GV-stage with full reversibility of the inhibitory effect. Different concentrations were tested: 0 (control), 0.001, 0.01, 0.1, 0.3, 1 and 10 μM. After 24 h of incubation with cilostazol, groups of cumulus-oocyte complexes (COCs) were denuded, and were classified by light microscopy as GV, GV breakdown (GVBD) or polar body extrusion (PB). Experiment 2 determined the spindle organization and chromosome alignment of IVM oocytes following removal of cilostazol, and the developmental potential of the resulting embryos fertilized by the ICSI method in the early stage of development and at full-term. Body weight and reproductive ability in offspring were also analyzed. Experiment 3 was an in vivo experiment which assessed whether cilostazol affected the fertility of mice, and the side effects induced by this drug.

Mice and collection of oocytes

ICR inbred mice (CD-1, Animal Center of Medical College of Peking University), at 8–10 weeks of age were housed and bred in the Animal Center of Medical College of Peking University according to national legislation for animal care. Mice at the preovulatory stage were injected intraperitoneally with 10 IU pregnant mare serum gonadotropin (PMSG) and sacrificed 48 h later by cervical dislocation in order to obtain COCs and denuded oocytes (DOs) from small antral follicles. The ovaries were dissected and collected in Leibovitz-15 medium, supplemented with 10% fetal calf serum (FBS, GIBCO), 100 mg/ml streptomycin, and 100 IU/ml penicillin. To prevent spontaneous resumption of meiosis, cilostazol or ORG9935 was added to this medium at the same final concentration as used in the IVM medium.
COCs and DOs were isolated mechanically by puncturing antral follicles with fine needles. Only DOs with a GV and COCs consisting of an oocyte surrounded by a compact cumulus-cell mass were selected for the experiments.

For in vivo experiments, oocytes were obtained by priming mice with 10 IU/ml PMSG followed at 48 h by an injection of 10 IU human chorionic gonadotropin (hCG). Two hours before injecting hCG, mice were given ORG9935 or cilostazol by feeding at concentrations of 30 mg/kg, 60 mg/kg, 150 mg/kg, 300 mg/kg, and 500 mg/kg. After sacrificing the mice, COCs were obtained from the oviduct. To assess oocyte development, we used 80 IU/ml hyaluronidase to remove the cumulus cells surrounding the oocytes.

In vitro maturation of oocytes
Immediately after aspiration, the oocytes were washed and placed into 15 μl droplets containing different concentrations of the drugs overlaid with oil. The IVM medium (Invitrogen, Sweden) was prepared the day before and supplemented with 10 U/L FSH and LH. The drugs were added to the IVM medium before oocyte retrieval. All cultures were carried out at 37°C in a humidified atmosphere in an incubator gassed with 5% CO2 in air. At 24 h of culture, the stages of oocyte development were recorded and oocytes with PB I were removed from culture. Oocytes were denuded mechanically by repeated pipetting and were assessed for maturation by scoring for GV, GVBD and PB1.

Table 3. Comparison of heart rate and blood pressure in mice before and after cilostazol administration (Mean ± S.E.M).

| Groups           | Blood pressure | Heart rate |
|------------------|----------------|------------|
|                  | SBP (mmHg)     | DBP (mmHg) |
| Before treatment | 105.475±4.134* | 67.788±4.058* |
| After treatment  | 108.100±4.375* | 70.075±4.200* |

*Values with same superscripts in the same column are comparable (P<0.05).

doi:10.1371/journal.pone.0030649.t003

Figure 5. Effects of cilostazol administration on the fertility of female mice. (A) treated with cilostazol, (B) treatment with cilostazol stopped. The value of the litter size is not a percentage, but numerical data. In image (A), Black solid rectangle represents cilostazol treatment group, and black hollow rectangle represents control group without cilostazol treatment. In image (B), Black solid rectangle represents cilostazol treatment group, but stopped treatment at present, and black hollow rectangle represents control group without cilostazol treatment.

doi:10.1371/journal.pone.0030649.g005
Immunofluorescence staining and confocal analysis

Mature (IVM) oocytes were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) in vitro for 30 min at room temperature. They were then permeabilized in incubation buffer (1% Triton X-100 in PBS) for 15 min at 37°C in an incubator. This was followed by blocking in 1% BSA for 1 h and overnight incubation at 4°C with rabbit anti-α-tubulin antibody (1:100) for spindle staining. After three washes in PBS with 0.1% Tween-20 and 0.1% Triton X-100 for 5 min, the oocytes were incubated with FITC-conjugated goat anti-rabbit IgG (1:100, Santa Cruz biotechnology, Inc, US) at 37°C for 1 h. The oocytes in the control group were only incubated with the FITC-conjugated secondary antibody. The oocytes were then incubated with PI at room temperature for 15 min. The oocytes were observed using a laser scanning confocal microscope (LSCM; Biorad Radiance 2000 mounted on a Nikon inverted microscope; Tokyo, Japan) to analyze spindle size, shape and chromosome alignment.

Intracytoplasmic sperm injection, embryo culture and embryo transfer

After removal of the drugs at 1 μmol/L, the oocytes were cultured in IVM medium for 20 h and MII oocytes were used for ICSI. Sperm collected from the cauda epididymis of adult ICR mice was washed twice with injection buffer (75 m mol/L KCl and 20 m mol/L HEPES, pH 7.0), then treated with buffer containing 12% polyvinylpyrrolidone. Active sperm was delivered into the oocyte cytoplasm using a Piezo micropipette-driving unit as described [32]. A slight piezo-electric pulse was applied to puncture the oocyte plasma membrane following penetration of the zona pellucida. Mouse sperm heads were separated from tails by applying a few piezo-pulses at the mid-piece of the sperm, immediately prior to injection into the oocyte. Activation was assessed by the number of zygotes with extrusion of the second PB by applying a few piezo-pulses at the mid-piece of the sperm. After ICSI manipulation, the embryos showing two-pronuclei (2PN) were transferred to the oviduct of pseudopregnant CD-1 females and the pregnant mice delivered naturally on day 19.5. The offspring were maintained under controlled temperature and lighting conditions, and given food and water ad libitum. Postnatal development of mice was evaluated according to a panel of physiological indices, including body weight and reproductive ability.

References

1. Jensen JT, Speroff L (2000) Health benefits of oral contraceptives. Obstetrics and Gynecology Clinics of North America 27(4): 705–721.
2. Kaunitz AM (1999) Oral contraceptive health benefits: perception versus reality. Contraception 59(1 Suppl): 298–338.
3. Channing CP, Hillensjo T, Schaerf FW (1978) Hormonal control of oocyte meiosis, ovulation and luteinization in mammals. Clinics in Endocrinology and Metabolism 7(3): 601–624.
4. Richards JS, Hedin I (1980) Molecular aspects of hormone action in ovarian follicular development, ovulation, and luteinization. Annual Review of Physiology 50: 441–465.
5. Taftari A, Chun SY, Zhang R, Huesh AJ, Conti M (1996) Oocyte maturation involves compartmentalization and opposing changes of CAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Developmental Biology 178(2): 397–403.
6. Wirtzma A, Hirsch B, Taftari A, Hansen RG, Van de Kant M, et al. (1998) Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents. The Journal of Clinical Investigation 102(3): 532–537.
7. Nogueira D, Albano C, Adriansen T, Cortivinsh B, Bourgain C, et al. (2003) Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biology of Reproduction 69(3): 1042–1052.
8. Jensen JT, Schwinof KM, Zelinski-Wooster MB, Conti M, DePaolo LV, et al. (2002) Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis in macaque oocytes in vitro. Human Reproduction (Oxford, England) 17(9): 2079–2084.
9. Jensen JT, Zelinski-Wooster MB, Schwinof KM, Vance JE, Stouffer RL (2005) The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation during gonadotropin-stimulated ovarian cycles in rhesus macaques. Contraception 71(1): 68–73.
10. Jensen JT, Zelinski MB, Stanley JE, Fauth JW, Stouffer RL (2008) The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques. Contraception 77(4): 303–307.
11. Jensen JT, Stouffer RL, Stanley JE, Zelinski MB (2010) Evaluation of the phosphodiesterase 3 inhibitor ORG 9935 as a contraceptive in female macaques: initial trials. Contraception 81(2): 165–171.
12. Kawamura K, Watanabe K, Kanura Y (1985) Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittel-Forschung 35(7A): 1149–1154.
13. Dowson DL, Culley BS, Meissner MH, Strandness DE, Jr. (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98(7): 670–686.
14. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Current Opinion in Cell Biology 12(2): 174–179.
15. Conti M, Andersen CB, Richard F, Melati C, Chun SY, et al. (2002) Role of cyclic nucleotide signaling in oocyte maturation. Molecular and Cellular Endocrinology 187(1–2): 153–159.
16. Sasseville M, Cote N, Guillemette C, Richard FJ (2006) New insight into the role of phosphodiesterase 3A in porcine oocyte maturation. BMC Developmental Biology 6: 47.
17. Racowsky C (1984) Effect of forskolin on the spontaneous maturation and cyclic AMP content of rat oocyte-cumulus complexes. Journal of Reproduction and Fertility 72(1): 107–116.
18. Richard FJ, Tsafir A, Conti M (2001) Role of phosphodiesterase type 3A in rat oocyte maturation. Biology of Reproduction 65(3): 1444–1451.
19. Thomas RE, Armstrong DT, Gilchrist RB (2002) Differential effects of specific phosphodiesterase isozyme inhibitors on bovine oocyte meiotic maturation. Developmental Biology 244(2): 215–225.
20. Nogueira D, Corverindt R, De Matos DG, Vanhoutte L, Smitz J (2003) Effect of phosphodiesterase type 3 inhibitor on developmental competence of immature mouse oocytes in vitro. Biology of Reproduction 69(6): 2045–2052.
21. Thomas RE, Thompson JG, Armstrong DT, Gilchrist RB (2004) Effect of specific phosphodiesterase isozyme inhibitors during in vitro maturation of bovine oocytes on meiotic and developmental capacity. Biology of Reproduction 71(4): 1142–1149.
22. Liang CG, Huo LJ, Zhong ZS, Chen DY, Schatten H, et al. (2005) Cyclic adenosine 3′,5′-monophosphate-dependent activation of mitogen-activated protein kinase in cumulus cells is essential for germinal vesicle breakdown of porcine cumulus-enclosed oocytes. Endocrinology 146(10): 4437–4444.
23. Vanhoutte L, De Sutter P, Nogueira D, Gerris J, Dhont M, et al. (2007) Nuclear and cytoplasmic maturation of in vitro matured human oocytes after temporary nuclear arrest by phosphodiesterase 3-inhibitor. Human Reproduction (Oxford, England) 22(5): 1259–1266.
24. Shu YM, Zeng HT, Ren Z, Zhuang GL, Liang XY, et al. (2008) Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes. Human Reproduction (Oxford, England) 23(5): 504–513.
25. Jee BG, Chen HY, Chian RC (2009) Effect of a phosphodiesterase type 3 inhibitor in oocyte maturation medium on subsequent mouse embryo development. Fertility and Sterility 91(3 Suppl): 2037–2042.
26. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, et al. (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. The Journal of Clinical Investigation 114(2): 196–205.
27. Nogueira D, Corverindt R, Evrareft B, Smitz J (2005) Effects of long-term in vitro exposure to phosphodiesterase type-3 inhibitors on follicle and oocyte development. Reproduction (Cambridge, England) 130(2): 177–186.
28. Liu Y, Shakur Y, Yoshitake M, Kamahaya JJ (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovascular Drug Reviews 19(4): 369–386.
29. Schror K (2002) The pharmacology of cilostazol. Diabetes, Obesity & Metabolism 4 Suppl 2: S1–19.
30. Shakur Y, Fong M, Hensley J, Cone J, Mosesian MA, et al. (2002) Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy 16(3): 417–427.
31. Wu SN, Liu SI, Huang MH (2004) Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Endocrinology 145(3): 1173–1184.
32. Kimura Y, Yanagimachi R (1995) Intracytoplasmic sperm injection in the mouse. Biology of Reproduction 52(4): 709–720.